Last Updated: November 8, 2026

Details for Patent: 9,586,955

« Back to Dashboard


Which drugs does patent 9,586,955 protect, and when does it expire?

Patent 9,586,955 protects EVRYSDI and is included in two NDAs.

This patent has forty-nine patent family members in twenty-nine countries.

Summary for Patent: 9,586,955
Title:Compounds for treating spinal muscular atrophy
Abstract:Provided herein are compounds of Formula (I): and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.
Inventor(s):Hongyan Qi, Soongyu Choi, Amal Dakka, Gary Mitchell Karp, Jana Narasimhan, Nikolai Naryshkin, Anthony A. Turpoff, Marla L. Weetall, Ellen Welch, Matthew G. Woll, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang, Xin Zhao, Luke Green, Emmanuel Pinard, Hasane Ratni
Assignee: Hoffmann La Roche Inc , PTC Therapeutics Inc
Application Number:US14/377,531
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,586,955
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 9,586,955

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Genentech Inc EVRYSDI risdiplam FOR SOLUTION;ORAL 213535-001 Aug 7, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Genentech Inc EVRYSDI risdiplam TABLET;ORAL 219285-001 Feb 11, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,586,955

PCT Information
PCT FiledFebruary 08, 2013PCT Application Number:PCT/US2013/025292
PCT Publication Date:August 15, 2013PCT Publication Number: WO2013/119916

International Family Members for US Patent 9,586,955

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 092794 ⤷  Start Trial
Australia 2013216870 ⤷  Start Trial
Australia 2017204248 ⤷  Start Trial
Brazil 112014019750 ⤷  Start Trial
Canada 2863874 ⤷  Start Trial
Chile 2014002100 ⤷  Start Trial
China 104349777 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.